REPL
NASDAQReplimune Group Inc.
Price$10.87-0.65 (-5.60%)
01:30 PM07:45 PM
News · 26 weeks61-33%
2026-04-192026-10-11
Mix3590d
- SEC Filings12(34%)
- Other10(29%)
- Insider7(20%)
- Analyst4(11%)
- Earnings1(3%)
- Leadership1(3%)
Latest news
25 items- NEWSREPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the FirmNEW YORK CITY, NY / ACCESS Newswire / October 2, 2026 / Levi & Korsinsky, LLP alerts investors in Replimune Group, Inc. (NASDAQ:REPL) that a securities class action has been filed on behalf of shareholders who purchased securities between October 20, 2025 and April 10, 2026. Check if you might be eligible to recover your investment losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or ☎(212) 363-7500.REPL shares fell from a Class Period high of $10.73 on December 8, 2025 to $1.70 on April 13, 2026, a cumulative decline of approximately 84.16%, or roughly $9.03 per share. The April 10, 2026 session alone took shares down $1.15 (19.46%) to $4.76 before a further $3.06
- PRReplimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced MelanomaWOBURN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that TUDRIQEV™ (vusolimogene oderparepvec-wtpg) is now commercially available in the United States. TUDRIQEV is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indi
- SECReplimune Group Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Replimune Group, Inc. (0001737953) (Filer)
- PRReplimune to Present at the Cantor Global Healthcare Conference 2026WOBURN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10 at 9:10 AM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the d
- INSIDERDirector Astley-Sparke Philip gifted 50,000 shares, decreasing direct ownership by 4% to 1,362,414 units (SEC Form 4)4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERChief Financial Officer Hill Emily Luisa sold $132,176 worth of shares (9,256 units at $14.28), decreasing direct ownership by 4% to 215,852 units (SEC Form 4) to satisfy withholding tax4 - Replimune Group, Inc. (0001737953) (Issuer)
- PRReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to Michelle DiNapoli, the Company’s Chief Commercial Officer. The inducement awards consist of a non-qualified stock option to purchase 150,000 shares of the Company's common stock and restricted stock units representing 100,000 shares of the Company's common stock. The option has an exercise price of $15.58 per share, which is equal to the closing price of the Company's common stock on the date of grant. The option has a 10-year term and will vest
- SECSEC Form S-3ASR filed by Replimune Group Inc.S-3ASR - Replimune Group, Inc. (0001737953) (Filer)
- SECReplimune Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Replimune Group, Inc. (0001737953) (Filer)
- PRReplimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate UpdateTUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to support commercial launch and confirmatory trial WOBURN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2026 and provided a business update. On August 6, 2026, the Company announced the U.S. Food and Drug Administration (FDA) has approved TUDRIQEV (vusolimogene oderpa
- INSIDERChief Executive Officer Patel Sushil sold $510,253 worth of shares (39,341 units at $12.97), decreasing direct ownership by 5% to 708,151 units (SEC Form 4) to cover taxes4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERChief Financial Officer Hill Emily Luisa sold $148,481 worth of shares (11,448 units at $12.97), decreasing direct ownership by 5% to 225,108 units (SEC Form 4) (for tax liability)4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERChief Medical Officer Xynos Konstantinos sold $148,468 worth of shares (11,447 units at $12.97), decreasing direct ownership by 5% to 224,215 units (SEC Form 4) (tax liability)4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERChief Accounting Officer Schwendenman Andrew sold $98,987 worth of shares (7,632 units at $12.97), decreasing direct ownership by 7% to 99,425 units (SEC Form 4) (withholding tax)4 - Replimune Group, Inc. (0001737953) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Replimune Group Inc.SCHEDULE 13D/A - Replimune Group, Inc. (0001737953) (Subject)
- INSIDERSEC Form 4 filed by Director Baker Bros. Advisors Lp4 - Replimune Group, Inc. (0001737953) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Replimune Group Inc.SCHEDULE 13G - Replimune Group, Inc. (0001737953) (Subject)
- PRReplimune Announces Pricing of $150 Million Underwritten OfferingBOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL) ("Replimune"), a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at an offering price of $12.06 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,736,340 shares of its common stock at a purchase price of $12.0599 per pre-funded warrant, which equals the offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering are expec
- SECReplimune Group Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Replimune Group, Inc. (0001737953) (Filer)
- SECSEC Form 424B5 filed by Replimune Group Inc.424B5 - Replimune Group, Inc. (0001737953) (Filer)
- SECSEC Form SCHEDULE 13G filed by Replimune Group Inc.SCHEDULE 13G - Replimune Group, Inc. (0001737953) (Subject)
- ANALYSTReplimune upgraded by Wedbush with a new price targetWedbush upgraded Replimune from Neutral to Outperform and set a new price target of $12.00
- SECReplimune Group Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Replimune Group, Inc. (0001737953) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Replimune Group Inc.SCHEDULE 13G/A - Replimune Group, Inc. (0001737953) (Subject)
- PRReplimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based RegimenBroad label to address high unmet need in advanced melanoma Replimune will host conference call on August 6, 2026 at 4:30 p.m. ET. WOBURN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for TUDRIQEVTM (vusolimogene oderparepvec-wtpg), previously referred to as RP1, in combination with nivolumab for the treatment of adults with unresectable advanced cutaneous melanoma who experienced disease progression on an anti-PD-1 antibody-based regimen.This indication
REPL FAQ
7 questionsWhat does Replimune Group Inc. do?
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an...Where does REPL stock trade?
Replimune Group Inc. (REPL) is listed on NASDAQ.What sector and industry is REPL in?
Replimune Group Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Replimune Group Inc. go public?
Replimune Group Inc. (REPL) completed its IPO in 2018.What are analysts saying about REPL?
Replimune Group Inc. has had 8 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $1200.00 price target on 2026-08-07.What companies are similar to REPL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare REPL side-by-side with any of them on Quantisnow.How can I track REPL on Quantisnow?
Quantisnow aggregates Replimune Group Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow REPL to receive live email and push alerts on every new disclosure.